05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune
system related diseases and disorders, complement-mediated
diseases and disorders, neurological diseases and disorders,
and ophthalmic diseases and disorders; pharmaceutical
preparations for the treatment of Guillain-Barré syndrome,
macular degeneration, geographic atrophy, Huntington's
Disease, amyotrophic lateral sclerosis (ALS), lupus, cold
agglutinin disease (CAD), chronic inflammatory demyelinating
polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services
in the field of pharmaceutical research and development;
providing medical and scientific research information in the
field of pharmaceuticals and clinical trials. Providing medical information; providing medical information
related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune
system related diseases and disorders, complement-mediated
diseases and disorders, neurological diseases and disorders,
and ophthalmic diseases and disorders; pharmaceutical
preparations for the treatment of Guillain-Barré syndrome,
macular degeneration, geographic atrophy, Huntington's
disease, amyotrophic lateral sclerosis (ALS), lupus, cold
agglutinin disease (CAD), chronic inflammatory demyelinating
polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services
in the field of pharmaceutical research and development;
providing medical and scientific research information in the
field of pharmaceuticals and clinical trials. Providing medical information; providing medical information
related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune
system related diseases and disorders, complement-mediated
diseases and disorders, neurological diseases and disorders,
and ophthalmic diseases and disorders; pharmaceutical
preparations for the treatment of Guillain-Barré syndrome,
macular degeneration, geographic atrophy, Huntington's
Disease, amyotrophic lateral sclerosis (ALS), lupus, cold
agglutinin disease (CAD), chronic inflammatory demyelinating
polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services
in the field of pharmaceutical research and development;
providing medical and scientific research information in the
field of pharmaceuticals and clinical trials. Providing medical information; providing medical information
related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune
system related diseases and disorders, complement-mediated
diseases and disorders, neurological diseases and disorders,
and ophthalmic diseases and disorders; pharmaceutical
preparations for the treatment of Guillain-Barré syndrome,
macular degeneration, geographic atrophy, Huntington's
Disease, amyotrophic lateral sclerosis (ALS), lupus, cold
agglutinin disease (CAD), chronic inflammatory demyelinating
polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services
in the field of pharmaceutical research and development;
providing medical and scientific research information in the
field of pharmaceuticals and clinical trials. Providing medical information; providing medical information
related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
(2) Providing medical information; providing medical information related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
(2) Providing medical information; providing medical information related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
(2) Providing medical information; providing medical information related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). (1) Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials.
(2) Providing medical information; providing medical information related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.
05 - Pharmaceutical, veterinary and sanitary products
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's Disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Providing medical information; providing medical information related to pharmaceuticals.
The present disclosure is generally directed to pharmaceutical compositions comprising anti-C1q antibodies and methods of making and using such compositions. In certain embodiments, such compositions are high concentration anti-C1q antibody formulations that exhibit low viscosity and high stability and can therefore be conveniently delivered to subjects in need thereof with reduced discomfort.
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.
The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an ocular disease (e.g., glaucoma or age-related macular degeneration). The age-related macular degeneration may be geographic atrophy.
The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glads (USA)
Annexon, Inc. (USA)
Inventor
Paz, Jeanne T.
Sankaranarayanan, Sethu
Yednock, Ted
Abstract
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating epilepsy, comprising administering to a subject an inhibitor of the classical complement pathway.
The present disclosure relates generally to methods of treating lupus nephritis in a subject in need thereof. The method comprises determining that the subject has at least one of the following characteristics: an elevated C4x level; an elevated C4x/C4 ratio, a reduced C4 level; an elevated C1sC1 inhibitor level; an elevated C1sC1 inhibitor/C1s ratio; a reduced C1s level; an elevated C2b level; an elevated C2b/C2 ratio; a reduced C2 level; or an elevated Pathogenic Anti-C1q Antibody 1 (PACA1) and/or Pathogenic Anti-C1q Antibody 3 (PACA3) level; wherein C4x is selected from C4a, C4b and C4d, and administering to the subject an inhibitor of the classical complement pathway.
The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an inherited retinal disease (IRD) (e.g., retinitis pigmentosa, choroideremia, Stargardt disease, cone-rod dystrophy, leber congenital amaurosis), X-linked RP, and Usher Syndrome or retinal detachment.
The present disclosure relates generally to antibodies with a single antigen-binding arm comprising a single antigen-binding arm and an Fc region such as a single-arm antibodies. The present disclosure also relates generally to the use of such antibodies such as treating a disease associated with complement activation.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
The present disclosure relates generally to methods of treating Huntington's disease in a subject in need thereof. The method comprises determining that the subject has an elevated level of C4a or an elevated C4a/C4 ratio; and administering to the subject an inhibitor of the classical complement pathway.
The present disclosure relates generally to antibodies with a single antigen-binding arm comprising a single antigen-binding arm and an Fc region such as a single-arm antibodies. The present disclosure also relates generally to the use of such antibodies such as treating a disease associated with complement activation.
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating Duchenne muscular dystrophy, Becker muscular dystrophy, Limb- Girdle Muscular Dystrophies (LGMD), Collagen Type VI-Related Disorders, Congenital Muscular Dystrophies (CMD) and Congenital Myopathies, Distal Muscular Dystrophies/Myopathies. The method comprises administering to a subject an inhibitor of the classical complement pathway, such as a C1 complex inhibitor, a C1 complex inhibitor, a C1q inhibitor, a C1s inhibitor, or a C1r inhibitor.
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating Duchenne muscular dystrophy, Becker muscular dystrophy, Limb- Girdle Muscular Dystrophies (LGMD), Collagen Type VI-Related Disorders, Congenital Muscular Dystrophies (CMD) and Congenital Myopathies, Distal Muscular Dystrophies/Myopathies. The method comprises administering to a subject an inhibitor of the classical complement pathway, such as a C1 complex inhibitor, a C1 complex inhibitor, a C1q inhibitor, a C1s inhibitor, or a C1r inhibitor.
The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an ocular disease (e.g., glaucoma or age-related macular degeneration). The age-related macular degeneration may be geographic atrophy.
The present disclosure relates generally to compositions and methods of preventing, reducing risk of developing, or treating an ocular disease (e.g., glaucoma or age-related macular degeneration). The age-related macular degeneration may be geographic atrophy.
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/00 - Drugs for immunological or allergic disorders
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Disclosed are compounds of formula I and II and pharmaceutically acceptable salts thereof. Also disclosed are methods of treating a neurodegenerative disorder, an inflammatory disease, an autoimmune disease, an ophthalmic disease or a metabolic disorder using the compounds disclosed herein.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 37/00 - Drugs for immunological or allergic disorders
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (USA)
ANNEXON, INC. (USA)
Inventor
Paz, Jeanne T.
Sankaranarayanan, Sethu
Yednock, Ted
Abstract
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating epilepsy, comprising administering to a subject an inhibitor of the classical complement pathway.
THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (USA)
ANNEXON, INC. (USA)
Inventor
Paz, Jeanne T.
Sankaranarayanan, Sethu
Yednock, Ted
Abstract
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating epilepsy, comprising administering to a subject an inhibitor of the classical complement pathway.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 25/00 - Drugs for disorders of the nervous system
The present disclosure relates generally to methods of treating a brain injury, preferably a traumatic brain injury, hypoxic brain injury, brain infection, or stroke, comprising administering to a subject an inhibitor of the complement pathway.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating frontotemporal dementia (FTD) or a variant of FTD, comprising administering to a subject an inhibitor of the complement pathway.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
The present disclosure relates generally to anti-C4 antibodies and anti-C4b antibodies and methods of using the same in the treatment of neurodegenerative disease.
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating spinal muscular atrophy, comprising administering to a subject an inhibitor of the complement pathway.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
55.
Anti-complement factor C1q Fab fragments and uses thereof
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 25/00 - Drugs for disorders of the nervous system
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
62.
METHODS FOR SCREENING FOR INHIBITORS OF COMPLEMENT SERINE PROTEASES
The present disclosure relates to methods for screening for inhibitors of complement serine proteases by measuring the interaction of a serine protease with a molecular probe in the presence and absence of test compounds.
This invention relates generally to methods of treatment for neurodegenerative diseases such as Alzheimer's disease, Alzheimer's-related diseases, and Huntington's disease, and more specifically to methods involving the inhibition of the classical pathway of complement activation. Certain aspects of the present disclosure are directed to methods and kits for treating or preventing Alzheimer's disease and/or Huntington's disease that include inhibiting the classical pathway of complement activation by neutralizing complement factor C1q, e.g., through the administration of antibodies, such as monoclonal, chimeric, humanized antibodies, antibody fragments, etc., which bind to C1q.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
The present invention relates generally to the generation and characterization of neutralizing anti-C1s monoclonal antibodies. The invention further relates to the use of such anti-C1s antibodies in the detection of complement factors of the classical complement activation pathway, such as C1s. Additionally, the antibodies of this disclosure are useful for the diagnosis and treatment of disorders associated with an increased activation of the classical complement pathway, in particular autoimmune disorders and neurodegenerative diseases, including neurodegenerative diseases with synapse loss, such as Alzheimer's Disease. Methods of treatment of autoimmune and neurodegenerative diseases are also provided.
THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (United Kingdom)
Inventor
Rosenthal, Arnon
Leviten, Michael
Willison, Hugh, J.
Mcgonigal, Rhona
Abstract
This invention relates generally to methods of treatment for Guillain-Barre' Syndrome (GBS) and, more specifically, to methods involving the inhibition of the classical pathway of complement activation. Certain aspects of the present disclosure are directed to methods of treating Guillain-Barre' syndrome (GBS) that include inhibiting the classical pathway of complement activation by neutralizing the complement factors C1q, C1r, or C1s, e.g., through the administration of antibodies, such as monoclonal, chimeric, humanized antibodies, antibody fragments, etc., which bind to one or more of these complement factors.
The present disclosure relates generally to methods of preventing, reducing risk of developing, or treating neuromyelitis optica (NMO) and, more specifically, to methods involving the inhibition of the classical pathway of complement activation.